<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Radioimmunotherapy (RIT) with <z:chebi fb="2" ids="33331">Yttrium</z:chebi>-90 (90Y) ibritumomab tiuxetan (Zevalin) combines the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> targeting attributes of a monoclonal antibody against the CD20 antigen and the pure beta-radiation of 90Y </plain></SENT>
<SENT sid="1" pm="."><plain>High efficacy and a favorable safety profile have been demonstrated in Phase II and III clinical trials enrolling patients with CD20+ B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (B-NHL) </plain></SENT>
<SENT sid="2" pm="."><plain>On the basis of these results, 90Y-ibritumomab tiuxetan was approved in the United States for the treatment of patients with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) or transformed B-NHL </plain></SENT>
<SENT sid="3" pm="."><plain>In the European Union its use was restricted to FL, refractory to or relapsed after rituximab </plain></SENT>
<SENT sid="4" pm="."><plain>There are a number of important clinical trials currently evaluating 90Y-ibritumomab tiuxetan in other subtypes of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> such as diffuse large-cell and mantle-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, as consolidation therapy or as part of myeloablative regimens </plain></SENT>
<SENT sid="5" pm="."><plain>In light of the constantly increasing clinical experience with RIT, clinicians face the challenge of how to best integrate this promising new treatment option into existing established treatment algorithms </plain></SENT>
<SENT sid="6" pm="."><plain>By incorporating the most recent data in this rapidly developing field, this review article focuses on current recommendations for the use of 90Y-ibritumomab tiuxetan in patients with malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, outlines future perspectives, and provides practical recommendations for patient management </plain></SENT>
</text></document>